Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Kotoe TakayoshiHitoshi KusabaMasato UenomachiKenji MitsugiChinatsu MakiyamaAkitaka MakiyamaKeita UchinoTsuyoshi ShirakawaYoshihiro ShibataYudai ShinoharaKyoko InadomiKenji TsuchihashiShuji AritaHiroshi AriyamaTaito EsakiKoichi AkashiEishi BabaPublished in: Cancer chemotherapy and pharmacology (2017)
The analysis indicates that combination CT for advanced SBA is associated with modest efficacy and safety, and bevacizumab-containing CT may contribute to favorable outcome in these patients.
Keyphrases
- small bowel
- computed tomography
- image quality
- end stage renal disease
- ejection fraction
- newly diagnosed
- locally advanced
- metastatic colorectal cancer
- positron emission tomography
- magnetic resonance imaging
- magnetic resonance
- squamous cell carcinoma
- radiation therapy
- squamous cell
- patient reported outcomes
- liver metastases